^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CBP-1019
i
Other names: CBP-1019, CBP1019, CBP 1019
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Coherent Biopharma
Drug class:
DNA topoisomerase inhibitor, Folate receptor 1 inhibitor, TRPV6 inhibitor
Related drugs:
3ms
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin (clinicaltrials.gov)
P1, N=128, Not yet recruiting, M.D. Anderson Cancer Center
New P1 trial • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • Avastin (bevacizumab) • 5-fluorouracil • Xtandi (enzalutamide capsule) • oxaliplatin • leucovorin calcium • CBP-1019
11ms
A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=260, Recruiting, Coherent Biopharma (Hefei) Co., Ltd. | Active, not recruiting --> Recruiting
Enrollment open
|
FOLR1 ( Folate receptor alpha ) • TRPV6 (Transient Receptor Potential Cation Channel Subfamily V Member 6)
|
CBP-1019
over1year
Bispecific-XDC: Novel First-in-Class Cancer Therapies From Concept to Clinical (ADC-USA 2023)
Describing CBP-1008: a FR/ TRPV6 targeted drug conjugate in Phase II pivotal studies of advanced ovarian cancer treatment; Exploring CBP-1018: a FR/ PSMA targeted drug conjugate in Phase Ib for prostate cancer therapy; Highlighting CBP-1019: TOP1i payload drug conjugate for unmet medical needs
Clinical
|
TRPV6 (Transient Receptor Potential Cation Channel Subfamily V Member 6)
|
CBP-1008 • CBP-1018 • CBP-1019
over1year
A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=260, Active, not recruiting, Coherent Biopharma (Hefei) Co., Ltd.
New P1/2 trial • Metastases
|
TRPV6 (Transient Receptor Potential Cation Channel Subfamily V Member 6)
|
CBP-1019
Share via
